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Threshold of Toxicological Concern (TTC) aids assessment of human health risks from exposure to low
levels of chemicals when toxicity data are limited. The objective here was to explore the potential
reﬁnement of exposure for applying the oral TTC to chemicals found in cosmetic products, for which
there are limited dermal absorption data. A decision tree was constructed to estimate the dermally
absorbed amount of chemical, based on typical skin exposure scenarios. Dermal absorption was calcu-
lated using an established predictive algorithm to derive the maximum skin ﬂux adjusted to the actual
‘dose’ applied. The predicted systemic availability (assuming no local metabolism), can then be ranked
against the oral TTC for the relevant structural class. The predictive approach has been evaluated by
deriving the experimental/prediction ratio for systemic availability for 22 cosmetic chemical exposure
scenarios. These emphasise that estimation of skin penetration may be challenging for penetration
enhancing formulations, short application times with incomplete rinse-off, or signiﬁcant metabolism.
While there were a few exceptions, the experiment-to-prediction ratios mostly fell within a factor of 10
of the ideal value of 1. It can be concluded therefore, that the approach is ﬁt-for-purpose when used as a
screening and prioritisation tool.
© 2016 International Life Sciences Institute Europe. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Background to the Threshold of Toxicological Concern
The Threshold of Toxicological Concern (TTC) concept originates
from the United States Food and Drug Administration's (U.S. FDA's)200 Brussels, Belgium.
illiams).
tute Europe. Published by Elsevidevelopment and application of the Threshold of Regulation (US
Food and Drug Administration 1982; 1993a; 1993b]. The
approach built on Frawley's (1967) attempt to “determine a level of
use of any food-packaging component which could be considered
to be safe, regardless of its degree of toxicity” and was initially
intended to deal with indirect food additives that pose a negligible
risk. The TTC concept proposes that de minimis exposure values can
be established for many chemicals, including those of unknown
toxicity, based on comparison with the known toxicity of a wide
range of compounds (Kroes et al., 2004). By assigning chemicals toer Inc. This is an open access article under the CC BY-NC-ND license (http://
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Cramer et al. (1976) and plotting chronic oral no-observed-effect
levels (NOELs) from animal data for the most sensitive systemic
toxicological endpoint, Munro et al. (1996,1999) demonstrated that
toxicity varies signiﬁcantly as a function of structural class. An
uncertainty factor of 100 was applied to the 5th percentile NOEL of
each Cramer class, and the resulting conservative TTC values are
intended to represent exposure thresholds belowwhich there is no
appreciable risk to human health over a lifetime of daily exposure
for chemicals of that class. TTC provides threshold toxicity values
for oral dosing in structural categories as Cramer classes I, II and III
(1800, 540, and 90 mg/d or 30, 9 and 1.5 mg/kg/d) respectively. In
some cases the oral NOEL derived from animal data might fail to
predict human toxicity for example where metabolism and uptake
differ between species.
The TTC concept has the potential to provide a pragmatic,
transparent, consistent and scientiﬁcally sound approach to the
prioritisation of chemicals. TTC utilises different systemic end-
points, such as developmental and reproductive toxicity, immu-
notoxicity and neurotoxicity (Barlow, 2005; Mueller et al., 2008).
An expert group organised by the European cosmetic industry
association studied the utility of the TTC approach in the safety
evaluation of cosmetic ingredients and end products. They
considered a number of issues related to the chemical nature and
effects of ingredients and their exposure when used as cosmetics,
including differences in metabolism between the dermal and oral
routes of application, and default adjustment factors for topically
applied cosmetics. The expert group concluded that, “overall the
TTC approach provides a useful additional tool for the safety eval-
uation of cosmetic ingredients and impurities of known chemical
structure in the absence of chemical-speciﬁc toxicology data”
(Kroes et al., 2007).
Kroes et al. (2007) evaluated 58 Cramer class III chemicals with
no observed adverse effect level (NOAEL) values of 1 mg/kg or less.
Also, the data were evaluated to determine whether the oral-route
toxicity could be used to predict dermal-route toxicity more accu-
rately by including metabolism in the liver (systemic) and ﬁrst pass
oral versus dermal metabolism.
In 2012, three independent non-food Scientiﬁc Committees of
the European Commission were jointly tasked with evaluating
potential applications of the TTC approach for human health risk
assessment of chemical substances (European Commission, 2012,
2013). Their opinion focused on the potential applications of the
TTC concept for cosmetics and other consumer products in relation
to their mandates. The Scientiﬁc Committees considered the TTC
approach, in general, “scientiﬁcally acceptable for human health
risk assessment of systemic toxic effects caused by chemicals pre-
sent at very low levels, as based on sound exposure information”.
However, they emphasised the need for a high level of conﬁdence
in (1) the quality and completeness of the toxicity databases; (2)
the reliability of the exposure data for the intended use of the
chemical; and (3) the appropriateness of any extrapolations in or-
der to apply the TTC approach in risk assessment. The safety of
dermal exposure can be assessed with conﬁdence by extrapolation
from oral toxicity data with reﬁnement of bioavailability rather
than assuming 100% absorption, thus increasing both the reliability
and regulatory acceptance of the TTC concept for cosmetic safety
assessment. Recently TTC has been re-evaluated and recommended
as a valid screening tool by the European Food Safety Authority &
World Health Organization (2015).
1.2. Cosmetic use patterns
Cosmetic products are common to every household in most
regions and cultures of the world and their use is driven mainly byour interest in personal appearance, hygiene, or feelings of well-
being. Depending on the reason for which a cosmetic product is
selected and used, the exposure proﬁles of its ingredients will
generally be predictable and serve as the basis for quantifying the
exposure to the cosmetic product. It is obvious that for cosmetics
applied to skin the percutaneous absorption of ingredients needs to
be considered, whereas for oral hygiene products such as mouth-
rinses and lip care products, different considerations of the expo-
sure routes are required to make a complete safety assessment.
Dermal exposure to cosmetic products can be categorised as
leave-on, in which the product remains on the application site for
its intended period of use, or rinse-off, where the products are
applied and shortly thereafter, rinsed away. Examining general use
patterns of cosmetic products reveals variable frequencies of use
per day, ranges of daily applied amounts, and differing periods of a
product's use, for example, seasonally for sunscreens, monthly for
permanent hair colour products, weekly for exfoliating cosmetics,
or daily for moisturisers. The use frequency is also inﬂuenced by
other factors such as variation in consumer preference (daily use of
day-creams containing UV ﬁlters), marketing (local versus global
advertising), changes in personal preferences, or product discon-
tinuations. While general use patterns can be shown, the exposure
assessment will usually require a case-by-case approach to account
for the factors pertinent to the speciﬁc cosmetic ingredient being
evaluated.
Exposure estimation is a key part of the safety assessment for
cosmetic products and their ingredients. Indeed, it is the exposure
that is factored together with the hazard data to characterise the
potential risk of an adverse outcome that might arise from using
cosmetic ingredients. The advantage and principal basis for using
the TTC approach for risk characterisation lies in its use for chem-
icals for which adequate systemic hazard (toxicity) data are not
available.
1.3. Dermal absorption and oral-to-dermal extrapolation
The application of TTC has commonly assumed oral uptake and
systemic exposure as the toxicity data are derived following oral
dosing. The default assumption (comparison with the unadjusted
oral TTC) assumes 100% oral bioavailability.
The different characteristics of dermal exposure and absorption
from oral ingestion mean that consideration of route-to-route
extrapolation offers an important reﬁnement when applying the
oral TTC for cosmetics which are topically applied. Following topical
application, absorption is generally lower compared to oral
administration, as a result of the barrier function of the skin's outer
layer (the stratum corneum (SC)), relative to the efﬁcient absorp-
tion which takes place through the epithelium of the gastrointes-
tinal (GI) tract (e.g. Scheuplein, 1971; Karadzovska et al., 2013). In
terms of systemic exposure, blood levels of a topically applied
chemical are typically much lower and take a longer time to reach a
maximum concentration than when orally dosed. Furthermore for
lipophilic molecules, a reservoir may form in the SC fromwhich the
release is prolonged.
Differences in bioavailability between dermal and GI routes may
also be inﬂuenced by differential ﬁrst pass metabolism of the
absorbed molecule and speciﬁc transport processes in the GI tract
and skin. Quantitatively, ﬁrst pass metabolism is generally less in
the skin (basal membrane) than the GI epithelium (Williams,
2008). Xenobiotic metabolising enzymes for which differences in
GI and skin levels may be signiﬁcant and inﬂuence absorption of
the parent molecule include esterases, conjugating enzymes,
alcohol dehydrogenases and acetyl transferases. Cytochrome p450
enzymes present at low levels extra-hepatically generally do not
reduce absorption of the parent molecule (Kroes et al., 2007;
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based pharmacokinetic modelling with example molecules has
indicated that at the oral NOEL exposure level systemic bioavail-
ability may be greater following dermal exposure compared to oral
for caffeine and hydroquinone (Gajewska et al., 2014). An advantage
of transdermal drug delivery compared to oral is that it avoids pre-
systemic metabolism and that differences in the metabolic proﬁle,
relative to that seen post-oral dosing can be anticipated
(Wiedersberg and Guy, 2014). Targeting drugs through the skin can
result in increased bioavailability with reduced metabolism and
greater efﬁcacy but this is not generally associated with toxicity.
Systemic bioavailability following dermal exposuremight be higher
than following oral for some chemical molecules but there is
limited evidence of increased toxicity. There could be higher sys-
temic exposure to chemical molecules that are corrosive and
damage the stratum corneum.
Available quantitative information on the uptake of cosmetic
chemicals across the skin has most often been derived from in vitro
studies where steady-state conditions often apply. Absorption in-
formation is usually given as the skin permeability coefﬁcient, kp,
(in cm h1 or cm s1) representing steady state ﬂux normalised by
the concentration gradient. Flux is also often quoted in mg cm2 h1
ormol cm2 h1 and themaximum ﬂux, Jmax can be calculated from
knowledge of the kp and the saturation solubility of the chemical in
the vehicle used (the majority of measurements being in aqueous
solution). Although less frequently reported than kp, Jmax is ulti-
mately more useful for risk assessment and is independent of the
vehicle, provided that the vehicle is saturated with the solute and
therefore providing equivalent thermodynamic activity (Zhang
et al., 2009). After a century of research, there is still incomplete
validation of how to use in vitro derived dermal ﬂux data to predict
systemic bioavailability and therefore toxicity. In particular a
number of points must be noted when using Jmax to characterise
dermal absorption of chemicals from cosmetics. Firstly, many cos-
metics are applied as a ﬁnite dose of small volume with the con-
centration of chemical ingredient well below saturation in the
vehicle. As a result, signiﬁcant depletion of the chemical by skin
penetration may occur and the actual ﬂux (J) observed will be less
than the Jmax. For most rinse-off products, the short time for which
they are left on the skin, up to a few hours, may be insufﬁcient for
steady state to be achieved. While the latter may be possible for
leave-on products, this will depend on the ‘loading’ of the chemical
in the formulation and whether this is enough to sustain the ﬂux
for the longer period of application. Inefﬁcient washing reducing
removal of cosmetics from the skin surface could potentially sus-
tain the ﬂux. Secondly, cosmetic formulations are complex and
comprise multiple ingredients and there may be chemical to
chemical interactions. The prediction of a chemical's ﬂux from
mixtures based on experimental data from a simple aqueous so-
lution must be made with considerable care, therefore. A particu-
larly important concern is that cosmetic products invariably
contain, inter alia, surfactants (such as fatty acids and alcohols) and
co-solvents (e.g., simple alcohols, propylene glycol), which are
recognised as skin penetration enhancers and can promote dermal
absorption of cosmetic ingredients (Osborne and Henke, 1997;
Williams and Barry, 2004; Lane, 2013). Although there have been
efforts to predict the impact of such compounds on the ﬂux of
pharmaceuticals across the skin (Moss et al., 2012; Santos et al.,
2012), there is no generally-agreed or validated approach to do so
at this time.
In the absence of acceptable experimental data, predictive
quantitative structure-penetration relationship (QSPR) models
have been used to estimate dermal uptake (e.g., Potts and Guy,
1992; Wang et al., 2006; Magnusson et al., 2004). Magnusson
et al. (2004), also clustered chemicals into ‘good’, ‘intermediate’and ‘bad’ skin penetrators based on predictions of Jmax using MW,
log P, Cw,sat, melting point and hydrogen bonding ability. Similarly,
Kroes et al. (2007) proposed that, if experimental data were not
available, dose absorbed adjustments of the 100% default ﬁgure
should be applied based on calculations of Jmax (in mg/cm2/h),
speciﬁcally ranking penetration into 3 classes of availability: i.e.,
80%, 40% and 10% for Jmax >10, 10 > Jmax > 0.01, and Jmax < 0.01,
respectively.
The model of Potts and Guy (1992) calculates kp (in cm h1)
fromwater based on permeant size (expressed as molecular weight
(MW)) and lipophilicity (expressed as the logarithm of the octanol-
water partition coefﬁcient P (log P)). The model equation was
derived from a database (n¼ 93) of experimental in vitro and in vivo
dermal absorption data for diverse chemicals
(18 < MW < 750; 3 < log P < þ6) (Flynn, 1990):
log kp ¼ ð0:71 log PÞ  ð0:0061MWÞ  2:7 (1)
One limitation of the Potts and Guy model is that kp is over-
predicted for highly lipophilic compounds, the skin permeability
of which can be (at least in part) controlled by the viable skin layers
below the SC. Cleek and Bunge (1993) recognised this deﬁciency
and derived a modiﬁed expression for the permeability coefﬁcient
(kp,mod) that acknowledges that the skin is not a simple hydro-
phobic membrane:
kp;mod

cm hr1

¼ kp
.n
1þ

kp
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
MW
p .
2:6
o
(2)
The model is based upon measurements of steady state ﬂux; as
discussed above, such conditions do not always apply for cosmetic
use. Because Eq. (2) predicts a chemical's permeability from awater
vehicle, the calculation of Jmax must involve the aqueous solubility
of the compound (Cw,sat), i.e.,
Jmax¼ kp;mod Cw;sat (3)
Validation of this predictive approach has been reported for
chemicals in the EDETOX database (Guy, 2010; Kroes et al., 2007),
for fragrance chemicals (Guy, 2010; Shen et al., 2014), and for
transdermally delivered drugs (Wiedersberg and Guy, 2014). In
each case, the predicted values of Jmax, based on Eq. (3), compared
favourably with experimental measurements taken from the liter-
ature. Whenever possible, the calculated Jmax were determined
using experimental values of log P and Cw,sat. In some cases how-
ever, one or both of these physicochemical parameters had not
been measured and they were therefore estimated from web-
accessible algorithms from ChemSpider and the Virtual Computa-
tional Chemistry Laboratory. Using these estimated values intro-
duced no obvious bias into the ﬁndings. Given the typical variability
observed in experimental Jmax, and given that the calculated values
of maximum ﬂux involve assumptions and approximations as
detailed above, the previous application of the model has consid-
ered a prediction “successful” when the ratio of experimental to
predicted results falls in the range 0.1e10 (i.e., an order of magni-
tude on either side of the ‘ideal’ value of 1). Generally speaking, this
level of validation has been comfortably achieved, and when
divergence has been found, it has been possible to identify plausible
reasons for the lack of agreement between theory and experiment
(e.g., presence of a penetration enhancer, very low dose of chemical
applied precluding attainment of anything close to an experimental
Jmax).
The goal of the research described here, therefore, is to develop
methods to incorporate dermal bioavailability into the use of TTC
for cosmetics. A decision tree workﬂow has been derived and
evaluated to determine and use estimates of dermal penetration
parameters to deﬁne systemic dose. In addition, it has been
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issues inﬂuencing differences between prediction and experi-
mental data.
2. Methods
2.1. Application of the TTC concept
To apply the TTC concept to cosmetics applied to the skin, one
can either develop a dermal TTC or adapt an oral TTC. The latter
approach, which is based on external dose, has been used but with
consideration of dermal exposure and absorption as recommended
by Kroes et al. (2007). Derivation of dermal-speciﬁc thresholds was
not pursued due to a lack of quality toxicity data following dermal
dosing to support derivation of a dermal TTC. Since there is sufﬁ-
cient understanding of oral absorption and skin permeability, the
oral-to-dermal extrapolation of TTC thresholds by combining the
absorption, distribution, metabolism and excretion (ADME)
knowledge and oral repeated-dose toxicity data was considered
more pragmatic. As the existing dermal absorption/skin perme-
ability databases did not contain sufﬁcient cosmetics-related
chemicals, a new resource based on the EDETOX database (www.
newcastle.ac.uk/edetox) (Soyei and Williams, 2004) and the Sa-
maras database (Samaras et al., 2012) enriched with cosmetics-
related chemicals has been established (www.cosmostox.eu).
2.2. Evaluation of dermal TTC
There are two possible approaches that may be taken in
applying the TTC concept to the dermal route of exposure. The ﬁrst
is route-to-route extrapolation, or the prediction of an equivalent
dermal dose and dosing regimen which produce the same toxico-
logical response as that obtained for a given oral dose and dosing
regimen, while taking into account differences in metabolism and
kinetics (Mueller et al., 2008). Alternatively, a database speciﬁc to
dermal toxicity studies could be assembled and used to derive
dermal-speciﬁc TTC values. Both approaches rely on grouping
substances into structural classes based on a decision tree approach
and using the resulting “Cramer classiﬁcation” as an indicator of
systemic toxicity (Cramer et al., 1976). However, the scheme
devised by Cramer and colleagues aims to classify and rank
chemicals according to their expected level of oral systemic toxicity.
Whether these criteria are applicable to systemic toxicity via the
dermal route of exposure is unknown.
Therefore, an attempt wasmade to assess the applicability of the
Cramer classiﬁcation scheme to systemic toxicity via the dermal
route of exposure.
A reference database containing NO(A)EL values for systemic
toxicity via the dermal route of administration in rats, mice and
rabbits was compiled. Data for a total of 140 substances were har-
vested from public databases (echemportal.org, 102 entries) as well
as the open peer-reviewed literature dating back to 1970 (38 en-
tries). Only repeat dose studies where the NO(A)EL for systemic
toxicity was lower than the LO(A)EL for local effects were included,
which excluded primary irritants and corrosive substances. For
studies retrieved via echemportal.org, only those experimental
studies with a Klimisch score of 1 (reliable without restriction), or 2
(reliable with restrictions) were selected. For data extracted from
the peer-reviewed literature, reliability was not formally assessed.
Multiconstituent substances, UVCBs (substances of unknown or
variable composition, complex reaction products, or biological
materials) and those lacking the minimum data requirements were
excluded. In cases where more than one NO(A)EL value was iden-
tiﬁed for the same substance, the most conservative value was
retained. Formany substances, the dermal NO(A)EL was the highestdose tested (i.e. no systemic toxicity was observed).
2.3. Application of oral TTC and prediction of systemic availability
To apply the oral TTC threshold values to cosmetic-related
chemicals, the degree of absorption/permeability of compounds
through the skin and the differences in systemic bioavailability
between dermal and oral uptake must be considered. This can be
achieved by determining the systemic availability following topical
application either from experimental dermal absorption data, or
from prediction of the dermal uptake. For molecules which are
metabolised pre-systemically, oral-to-dermal differences in local
metabolismwill need to be considered and experimental data may
need to be obtained. The Lipinsky rule of 5 can be used to predict
whether a molecular structure will be orally available, but for some
molecules local metabolism in the GI tract must be considered
when applying the oral TTC.
The Potts and Guy (1992) model, with Cleek and Bunge's (1993)
correction for lipophilic molecules, has been used here to generate
kp and Jmax values, preferably whenever possible from experi-
mental data for log P and Cw,sat (as described above). It is recognised
that predictive algorithms to estimate these physicochemical pa-
rameters are available too, but that the predictive values can
sometimes differ substantially from one another (especially
aqueous solubilities) (Guy, 2010). Shen et al. (2014) provided
guidance on the selection of estimated physicochemical parame-
ters and recommended use of the mean, or mean þ 1SD, from
several different models to estimate log P and water solubility, if
experimental data were not available. It was concluded that these
predictions (which are based on dermal uptake from aqueous so-
lution) were relatively conservative compared to published exper-
imental data and that the approach may have value therefore, for
regulatory purposes.
To incorporate the effects of chemical absorption/permeability
across the skin in the TTC evaluation process, a decision tree was
designed using a prediction of Jmax when no relevant absorption
data were available. Obviously, if there are robust experimental
data from an in vitro absorption study reproducing the in vivo
exposure scenario to the product, it is appropriate to use this in-
formation to calculate the systemic dose. It seems reasonable to
hypothesise that either of these approaches must represent an
improvement on the current default assumption of 100%
absorption.
When no useful measurements are available, as discussed above
and later in Section 3.2, Jmax can be estimated and the maximum
amount (Qmax) of chemical entering the systemic circulation pre-
dicted. The calculation requires the permeability coefﬁcient (kp,mod)
derived from the Potts and Guy equation and the aqueous solubility
of the chemical (Caq,sat) The Cleek and Bunge modiﬁed value is used
for molecules with log p greater than 4.5:
Jmax

mg cm2 hr1

¼ kp;mod

cm hr1

 Caq;sat

mg cm3

(4)
QmaxðmgÞ ¼ A

cm2

 Jmax

mg cm2 hr1

 TexpðhrÞ (5)
In reality, the cosmetic product formulation may not be water,
nor saturated with the active compound of interest and may
contain ingredients that enhance skin penetration (e.g. surfactants,
fatty alcohols etc.). These and other factors may impact on the
actual skin ﬂux result. Eq. (4) assumes that there is no diffusional
lag time, no depletion of chemical from the skin surface (e.g., by
evaporation or abrasion), and that penetration stops at the end of
the exposure time. The validity of the non-depletion assumption
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Furthermore, it is widely accepted that uptake of chemical into the
body does not cease immediately when the product is removed
from the skin. The ability of (in particular) lipophilic compounds to
form so-called ‘reservoirs’ in the skin, from which continued
release may occur over a prolonged period, is well known. How-
ever, this under-estimate of the total amount absorbed is, in large
part, compensated for by the assumption of no diffusional lag-time
(i.e., that the ﬂux equals Jmax from the moment of product
application).
The following tiered decision tree approach for systemic
bioavailability depicted schematically in Fig. 1 has been developed
with a number of sequential steps requiring yes/no decisions.
Step 1: Are there exposure/absorption data available for the
compound of interest that allow the systemic dose to be esti-
mated? If yes, the TTC paradigm can be applied. If no, thenFig. 1. Tiered decision tree approach for the prediction of systemiccontinue to step 2. If the absorption data available were ob-
tained based on an in vitro study using an applied dose that
differs greatly from that in a typical exposure scenario, then the
decision tree approach should also be followed.
Step 2: Obtain chemical formula and structure. Does the
cosmetic compound fall within the deﬁned chemical space for
TTC and can the appropriate Cramer class be assigned (e.g., us-
ing ToxTree) and can a predicted J max be derived? If yes, move
to step 3. The approach has not been evaluated for metal salts,
ionised compounds or high MW macromolecules or polymers.
Step 3: Deﬁne typical cosmetic exposure scenarios for the
formulation; ascertain chemical concentration, formulation
composition.
Step 4: Estimate exposure to the chemical in typical exposure
scenarios, e.g. leave-on single dose, rinse-off, repeat doses, etc.
Use authoritative sources for skin contact times and exposed
areas (European Commission, 2012).availability of a dermally applied cosmetic ingredient.
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oral TTC. If exposure exceeds appropriate TTC value, move to
step 6.
Step 6: Obtain values of MWandwhere possible, experimentally
determined measures of log P and aqueous solubility. If the
latter are not available, then use available predictive algorithms
(including EPISuite, Chemspider, Virtual Computational Chem-
istry Laboratory, ToxTree, OECD QSAR Toolbox) to calculate
mean values of these parameters (eliminating outliers with an
appropriate statistical test). Either obtain kp or Jmax needed for
estimation from the COSMOS database or calculate using the
Potts and Guy approach (Eqs. (2) and (3) (Guy, 2010). Use Jmax
to calculate Qmax in step 7.
An alternative at this stage is to use the default assumption for %
absorption based on Kroes et al. (2007) to obtain a conservative
estimate of systemic availability by ranking Jmax into 3 classes of
availability: i.e., 80%, 40% and 10% for Jmax >10, 10 > Jmax > 0.01, and
Jmax < 0.01, respectively to compare to TTC.
Step 7: Calculate maximum systemic availability (Qmax) from Eq.
(4) in units of mg/cm2 or mg/cm2/kg body weight.
Step 8: Compare the maximum systemic availability with oral
TTC. If Qmax exceeds TTC, or even 100% exposure/absorption,
then proceed to step 9. If not, use estimate in your assessment.
Step 9: Reﬁne prediction by calculating a modiﬁed systemic
availability (Qcorr) using DS (degree of saturation) the actual
concentration of chemical in the formulation (C) relative to its
solubility therein (Csat), i.e.,
Qcorr ¼ A Jmax  Texp  C=Csatð Þ (6)
The calculations in steps 6 to 9 are based on the assumptions
that (i) a chemical's ﬂux from any vehicle will be the same if the
degree of its saturationwithin the formulation is kept constant, and
(ii) the vehicle/formulation does not change the skin's barrier
function or enhance penetration so actual ﬂux relates to concen-
tration (some molecules inappropriate to proceed). If Csat in
formulation is not available use aqueous Csat as default.
Step 10: Compare Qcorr with oral TTC. If the TTC threshold is
much greater than the estimated systemic availability, the
assessment passes and there is no concern. In cases where the
systemic availability exceeds or approaches the TTC, an expert
assessment is warranted to evaluate the conﬁdence in the es-
timate or re-evaluate conservatism of assumptions. Systemic
exposure may be under predicted in cases of non-aqueous for-
mulations, the presence of penetration enhancers or short
residence times.
Step 11: If the assessment fails in Step 10, expert judgement will
determine whether further information or experimental data
may be required.1 Additional information about the categorization of substances by Toxtree are
available from the European Commission’s Joint Research Centre (http://ihcp.jrc.ec.
europa.eu/our_labs/predictive_toxicology/qsar_tools/toxtree).3. Results
3.1. Evaluation of dermal TTC
The 140 chemicals selected for inclusion in the reference data-
base represent a range of industrial and consumer chemicals, with
52 of the substances (37%) being used in cosmetics currently
marketed in Canada (Health Canada, 2013). An additional 28 sub-
stances (20%) had INCI names and/or were listed in CosIng, the
European Commission's inventory of cosmetic ingredients, but
were not presently identiﬁed in cosmetics on the Canadian market.
Therefore, it can be surmised that roughly half these substances arecurrently or may potentially be used in cosmetics. The allocation of
chemicals to Cramer classes was performed with the extended
version of the Cramer decision tree of the open source program
Toxtree-v2.5.0 (Patlewicz et al., 2008)1. Of the 140 chemicals, 44
were assigned to Cramer class I, 5 to Cramer class II and 91 to
Cramer class III. This distribution is similar to the Munro dataset
(Munro et al., 1996) used to derive the oral TTC values (Table 1).
The cumulative distribution of the NO(A)ELs (animal derived
data) of substances separated into Cramer structural classes ap-
pears in Fig. 2. As observed by Munro et al. (1996) for the oral route
of exposure, there is a clear effect of chemical structure on systemic
toxicity via the dermal route, as indicated by the distinct separation
of the cumulative distributions for Cramer classes I and III. With
only 5 substances falling into Cramer class II, this group was
excluded from further analysis. The 50th percentiles of the distri-
butions were 500 and 200 mg/kg bw/d for structural classes I and
III, respectively, and the difference in means between the two
groups was statistically signiﬁcant (T-test for independent means,
T ¼ 3.89, p ¼ 0.000155). The 5th percentiles of the distributions of
NO(A)ELs were 35.3 and 5.0 mg/kg bw/d for class I and III,
respectively. Therefore, although the number of substances is
relatively small, these results strongly suggest that the Cramer
classiﬁcation scheme is still applicable to the ranking of chemicals
according to their expected level of systemic toxicity, even when
the route of exposure is dermal.3.2. Evaluation of the tiered decision tree approach for prediction of
systemic availability
The tiered decision tree is outlined step by step in the methods
and is shown schematically in Fig. 1. A worked case study example
for acid orange 7 is shown in Table 2. Acid Orange 7 passed when
related to TTC using the decision tree and new data from SCCS
(0.25 mg/cm2) will also clear the use of Acid Orange 7 in a cosmetics
product at 0.5% in formulation if there are no compound-speciﬁc
toxicity data (Scientiﬁc Committee on Consumer Safety, 2014).
Cosmetic exposure scenarios for 19 cosmetic chemicals and 3
contaminants were used as examples for application of the decision
tree to compare prediction with experimental data. Table 3 sum-
marises the physicochemical properties of the chemicals, the Jmax
and Qcorr predictions from the decision tree and for comparison
the experimental results. The molecules considered covered a
range of log P values characteristic of the compounds from which
the Potts and Guy algorithm was derived (with the possible
exception of zinc pyrithione and resorcinol). Chemicals were
mostly chosen from among those for which there is SCCS accepted
experimental data. Toxicity data exist for all of the examples pre-
sented, meaning that a TTC would not be used for these chemicals
in practice; however, they serve as useful cases for checking the
validity of the approach.
The experimental/prediction ratios (Qexpt/Qcorr) are shown in
Table 3 and graphically in Fig. 3 and mostly fall within the range
0.1e10 with many close to the ideal value of 1. For the examples
considered in this paper, the predicted ﬂuxes are compared to
experimental values obtained using a variety of vehicles. Results
were supportive of the application of the approach even for
cosmetic scenarios where formulations are not aqueous. The pre-
diction underestimated availability for zinc pyrithione, but the
Potts and Guy equation has not been evaluated for ionisable com-
pounds. Predictions for kojic acid showed good agreement, despite
Table 1
Allocation of substances by Cramer class for systemic toxicity following dermal dosing and oral toxicity from Munro et al. (1996).
Cramer class N (N%)
Repeat dose dermal esystemic effects (this study, N ¼ 140) I 44 (31%)
II 5 (4%)
III 91 (65%)
Chronic oral toxicity e original TTCs (Munro database, N ¼ 631) I 137 (22%)
II 28 (5%)
III 448 (73%)
Fig. 2. Cumulative distribution of the most conservative NO(A)ELs for systemic toxicity following repeat dose dermal administration for compounds divided into Cramer structural
classes I, II and III (Cramer et al., 1976).
Table 2
Example of application of the tiered decision tree to assessing exposure to acid orange 7.
Step Acid orange 7:
Rinse off exposure scenario of a hair dying client:
3 A(scalp) ¼ 560 cm2;
(t) ¼ 30 min/d;
dose 20 mg/cm2;
concentration of 0.5% w/w 5 mg/mL
4 Maximum (default) daily exposure to chemical is 0.9 mg/kg/d
5 Compare with oral TTC: Oral (1.5 mg/kg/d) < Dermal exposure
FAIL
6 Do we have experimental absorption data in COSMOS skin permeability database?
NO* - > use Potts-Guy to calculate.
7 Predict systemic availability Qmax
 Jmax ¼ 0.0144 mg/cm2/hr (exp. logP ¼ 1.4, MW ¼ 750.3, aq solubility ¼ 110 mg/mL)
 Qmax ¼ 4.032 mg/60 kg ¼ 0.068 mg/kg/day
8 Compare with oral TTC: Oral (1.5 mg/kg/d) < Dermal exposure
FAIL
9 Correct systemic Qmax for C/Csat: Qmax (corr) ¼ 3.03 mg/kg/d
10 Oral TTC ~ dermal availability
PASS
F.M. Williams et al. / Regulatory Toxicology and Pharmacology 76 (2016) 174e186180the data being derived from skin absorption studies with non-
aqueous formulations. Consideration of the extensive experi-
mental data for different formulations and uses of DEGEE, illus-
trates that the prediction is acceptable except for formulations of
DEGEE with short residence times (rinse-off) and in these cases,
experimental exposure exceeded the estimate by factors of 3e18.
Predictions for arbutinwere low, compared to experimental data in
some, but not all cases. For retinol, skin uptake was over-estimated,
but this very lipophilic compound has a log P that falls outside the
range encompassed by data that was used to develop the Potts &Guy algorithm and is locally metabolised, underlining the impor-
tance of applying expert judgment to this approach. Methyl ben-
zylidine camphor and benzophenone-3 formulations were
saturated and a value of 1 used for DS (the concentration ratio), i.e.
no correction was appropriate. The (Qexpt/Qcorr) ratio for triclo-
carban, acid orange 7, methylisothiazolinone and quercetin was
between 0.1 and 10. For butyl paraben the experimental studies
reported that skin penetration of butyl paraben was low, but sig-
niﬁcant amounts (more than 10-fold higher) of a degradation
product (likely due to local hydrolysis in the skin) and not included
Table 3
Skin absorption values predicted derived from Potts and Guy equation and experimentally determined for 19 cosmetic chemicals in 54 formulations and for three impurities.
Chemical MW log P Csat (mg/
cm3)
Kp, *corr
(cm/h)
Jmax (mg/
cm2/h)
Product Exposure time
(h)
Dose applied (mg/
cm2)
Area
(cm2)
Qmax (mg/
cm2)
Capp (mg/
cm3)
DS ¼ C/
Capp
Qexp (mg/
cm2)
Qcorr (mg/
cm2)
Qexp/
Qcorr
Basic blue 124a) 305.8 1.79 150 1.56E-06 0.23407 hair dye 0.5 100 560 0.11703 5 0.0333 0.017 0.0039 4.36
Zinc pyrithioneb) 317.7 0.9 0.015 1.08E-04 0.00161 water, CMC 8 100 500 0.01291 0.015 1 1.32 0.01291 102
Kojic acidc) 142.1 0.64 44 9.82E-05 4.32051 Cream 16 21 500 69.128 10.5 0.24 3.58 16.496 0.22
Arbutind) 272.3 1.35 100 5.09E-06 0.509 Cream 24 346.5 500 12.22 63 0.63 6.31 7.7 0.82
Arbutind) 272.3 1.35 100 5.09E-06 0.509 Cream 24 165 500 12.22 30 0.3 0.21 3.66 0.06
Arbutind) 272.3 1.35 100 5.09E-06 0.509 Cream 24 346.5 500 12.22 63 0.63 0.49 7.7 0.06
Arbutind) 272.3 1.35 100 5.09E-06 0.509 Cream 24 165 500 12.22 30 0.3 0.35 3.66 0.1
Arbutind) 272.3 1.35 100 5.09E-06 0.509 Gel 24 346.5 560 12.22 63 0.63 0.49 7.7 0.06
Arbutind) 272.3 1.35 100 5.09E-06 0.509 Gel 24 165 560 12.22 30 0.3 0.26 3.66 0.07
Butoxyethanole) 118.2 0.8 100 0.00144 143.11 hair dye 0.5 600 560 71.56 30 0.3 61 21.47 2.84
Butoxyethanole) 118.2 0.8 100 0.00144 143.11 hair dye 0.5 120 560 71.56 50 0.5 125 35.78 3.49
Benzophenone-3f) 228.3 3.7 0.0037 *0.0298 0.11 sunscreen 24 200 500 2.65 0.0037 1 7.90 2.65 2.98
Benzophenone-3f) 228.3 3.7 0.0037 *0.0298 0.11 sunscreen 24 600 500 2.65 0.0037 1 18.30 2.65 6.91
Benzophenone-3f) 228.3 3.7 0.0037 *0.0298 0.11 sunscreen 24 200 560 2.65 0.0037 1 6.7 2.65 2.53
Benzophenone-3f) 228.3 3.7 0.0037 *0.0298 0.11 sunscreen 24 600 500 2.65 0.0037 1 19.30 2.65 7.29
Me-Benzilidene
camphorg)
254.4 5.95 0.0002 *0.14 0.028 sunscreen 24 180 500 0.672 0 1 1.5 0.672 2.231
2-nitro-5-glyceryl-
MeAnilineh)
242 1.14 1.43 0.000454 0.65 hair dye 0.5 180 560 0.32 1.43 1 0.51 0.32 1.58
Retinoli) 286.5 6.72 0.0067 *1.44 0.963 Gel 24 6 500 23.12 0.0067 1 0.360 23.12 0.02
Retinoli) 286.5 6.72 0.0067 *1.44 0.963 Emulsion 24 6 500 23.12 0.0067 1 0.612 23.12 0.03
Benzisothiazolinonej) 151.2 0.7 1.1 0.000775 0.849 Cream 24 2 560 20.38 0.1 0.09 1.04 1.85 0.56
DEEGEk) 134.2 0.54 1000 0.000129 128.96 Shampoo 0.5 279 560 64.48 50 0.05 60.5 3.22 18.77
DEEGEk) 134.2 0.54 1000 0.000129 128.96 shampoo 0.5 530 560 64.48 100 0.1 92.2 6.45 14.3
DEEGEk) 134.2 0.54 1000 0.000129 128.96 gel 24 831 500 3095 150 0.15 425 464.25 0.92
DEEGEk) 134.2 0.54 1000 0.000129 128.96 gel (occlusive) 24 859 500 3095 150 0.15 385 464.25 0.83
DEEGEk) 134.2 0.54 1000 0.000129 128.96 repeated occl 24 890 500 3095 150 0.15 459 464.25 0.99
DEEGEk) 134.2 0.54 1000 0.000129 128.96 emulsiﬁed 24 100 500 3095 20 0.02 43.7 61.9 0.71
DEEGEk) 134.2 0.54 1000 0.000129 128.96 emulsiﬁed 24 287 500 3095 50 0.05 140 154.75 0.9
DEEGEk) 134.2 0.54 1000 0.000129 128.96 emulsiﬁed 24 570 500 3095 100 0.1 267 309.5 0.86
DEEGEk) 134.2 0.54 1000 0.000129 128.96 emulsiﬁed 24 100 500 3095 20 0.02 52.7 61.9 0.85
DEEGEk) 134.2 0.54 1000 0.000129 128.96 emulsiﬁed 24 285 500 3095 50 0.05 128 154.75 0.83
DEEGEk) 134.2 0.54 1000 0.000129 128.96 emulsiﬁed 24 570 500 3095 100 0.1 294 309.5 0.95
DEEGEk) 134.2 0.54 1000 0.000129 128.96 repeated occl 24 100 500 3095 20 0.02 59.5 61.9 0.96
DEEGEk) 134.2 0.54 1000 0.000129 128.96 repeated occl 24 285 500 3095 50 0.05 167 154.75 1.08
DEEGEk) 134.2 0.54 1000 0.000129 128.96 repeated occl 24 570 500 3095 100 0.1 319 309.5 1.03
DEEGEk) 134.2 0.54 1000 0.000129 128.96 hair dye 0.5 400 560 64.48 20 0.02 8.40 1.29 6.51
DEEGEk) 134.2 0.54 1000 0.000129 128.96 hair dye 0.5 700 560 64.48 35 0.04 13.80 2.26 6.11
DEEGEk) 134.2 0.54 1000 0.000129 128.96 hair dye 0.5 1400 560 64.48 70 0.07 34.20 4.51 7.58
DEEGEk) 134.2 0.54 1000 0.000129 128.96 hair dye 0.5 200 560 64.48 10 0.01 3.70 0.64 5.74
DEEGEk) 134.2 0.54 1000 0.000129 128.96 hair dye 0.5 600 560 64.48 30 0.03 8.30 1.93 4.29
DEEGEk) 134.2 0.54 1000 0.000129 128.96 hair dye 0.5 1000 560 64.48 50 0.05 9.90 3.22 3.07
Diethyl phthalatel) 222.2 2.4 1 *0.00456 2.61 whole body 24 100 17,500 62.67 1 1.75 1008 109.36 9.22
Acid orange 7m) 350.3 1.4 110 0.000155 17.08 hair client 0.5 100 560 8.54 8 0.07 0.04 0.621 0.06
Acid orange 7m) 350.3 1.4 110 0.000155 17.08 Hair 0.5 20 560 8.54 5 0.05 0.07 0.39 0.18
Acid orange 7m) 350.3 1.4 110 0.000155 17.08 hair client 0.5 20 560 8.54 5 0.05 0.95 0.39 2.45
Acid orange 7m) 350.3 1.4 110 0.000155 17.08 hair client 0.5 10 560 8.54 2 0.02 0.04 0.16 0.26
Butyl parabenn) 194.2 3.47 1 *0.0327 32.69 leave on 24 7.9 17500 784.57 1 1 3 784.57 0.0038
Triclocarbano) 315.6 4.9 0.00065 *0.0504 0.03 shower wash off 0.07 0.9 560 0 0.15 230.77 1.5 0.53 2.84
Quercetinp) 302.2 1.48 2472 0.000344 848.81 cosmetic leave on
2  1.3
12 0.366 500 10,185.71 1 0.00041 0.23 4.12 0.06
Methylisothiazolinoneq) 115.2 0.83 748 0.000104 78.12 hair stylist wash off 1.3 215.5 860 101.56 0.1 0.00013 0.1 0.01 7.37
(continued on next page)
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F.M. Williams et al. / Regulatory Toxicology and Pharmacology 76 (2016) 174e186182in the experimental measurement were observed in the receptor
compartment of the in vitro diffusion cell. The predicted absorption
would include both butyl paraben and its degradation product and
would be within an order of magnitude of that observed experi-
mentally. Appropriate experimental data were not available in
some cases and assumptions have been made, for example for
diethyl phthalate. When considering potential impurities, the
prediction for dioxane was poor and largely over-estimated, most
likely because the chemical is highly volatile and a substantial
fraction of the ‘dose’ evaporates before absorption can occur. The
predictions for hydrazine and acrylamide, on the other hand,
aligned well with experimental data.
Two cosmetic impurities provide illustrations of how the deci-
sion tree approach might be used in conjunction with oral TTC to
determine whether a chemical in a cosmetic may or may not raise a
potential exposure risk alert. Hydrazine (which is, in fact, pro-
hibited as an ingredient in cosmetics) may occur as a residual in
polyvinylpyrrolidone (PVP), a polymer typically used in cosmetics
at concentrations of 0.3e10% w/w. If hydrazine was present as a
residual in PVP at 1 ppm, this would equate to a level of 3e100 ng/g.
In Table 4, the Jmax and Qcorr predictions from Table 3 for hydrazine
are used to calculate a daily exposure to the chemical based on the
use of a leave-on face cream product. This predicted systemic ‘dose’
is then compared with the relevant TTC value and it is found that
the two differ only by a factor of about 3. If such case occurred with
a substance lacking repeated dose toxicity data, careful evaluation
would be necessary to determine if the estimate of dermal avail-
ability is reliable. Acrylamide monomers represent a common re-
sidual of several polycationic polymers (so-called
“polyquaterniums”) used in personal care products. Table 2 com-
pares the oral TTC with the decision tree derived predicted daily
exposure when acrylamide is present at 10 ppm in a leave-on body
lotion (containing 3% of a polyquaternium) over the entire torso,
and excluding the head. In this case, the ratio of TTC divided by
predicted exposure is greater than 5.
The alternative approach proposed by Kroes et al. (2007) for
prediction of dermal bioavailability extrapolated from Jmax to a %
absorbed which could then be applied to the actual exposure sce-
nario. Kroes proposed ranking penetration into 3 classes of avail-
ability: i.e., 80%, 40% and 10% for Jmax >10, 10 > Jmax >0.01, and
Jmax <0.01, respectively although gave no reason for the cut off
values used. Shen et al. (2014) demonstrated that this conservative
approach could be applied to ﬁne fragrancematerials. The results of
this approach for the cosmetic scenarios considered with the de-
cision tree are shown in Fig. 4 for comparison with Fig. 3. Fig. 4
contains the ratio Q experimental to Q derived from the Kroes
binning. The predictions were conservative and higher than the
decision tree approach and for many of the molecules the ratio was
less than 0.1.
As highlighted at step 9 of the decision tree there are limitations
of the decision tree approach. First, the default starting point is to
estimate a chemical's potential maximum ﬂux across the skin,
assuming that it is saturated in the formulation. If this is not the
case (and usually it is not), then the estimated ﬂux must be cor-
rected to a smaller and more realistic value by multiplying Jmax by
the degree of saturation (DS) of the chemical in the formulation.
This is simple when the formulation is water-based, but may
require experimental measurement when the formulation is oil, for
example, and the solubility of the chemical therein is not known.
Second, while the maximum ﬂux is the key predictor used here, the
calculation assumes that the formulation has no effect on skin
barrier function e that is, the vehicle is considered benign with no
skin penetration enhancing components. With respect to the
example chemicals considered here, with the exception of butyl
paraben (see above), extensive metabolism in the GI tract or skin
Fig. 3. Comparison of the experimentally determined Q exp and theoretically predicted Qcorr dermal absorption for 19 cosmetic chemicals in 54 formulations and for three
impurities. The ratio of Qexp to Qcorr is shown. The optimum ratio would be 1. Values refer to chemicals as in Table 3.
F.M. Williams et al. / Regulatory Toxicology and Pharmacology 76 (2016) 174e186 183does not occur; this will not be true for all compounds however
(e.g., certain fragrance chemicals which are esters (Shen et al.,
2014)).4. Discussion
A decision tree based on the Potts and Guy equation, has been
developed to predict systemic availability derived from kp and Jmax,
and Jmax adjusted for the actual exposure scenario/concentration.
This decision tree offers a quantitative approach which has been
established on scientiﬁc principles and an understanding of dermal
absorption processes. The approach allows systemic availability to
be estimated within an order of magnitude of the experimental
results for many but not all cosmetic chemicals. The results of this
study indicate that it is possible to evaluate cosmetic substances
and their use scenarios and relate dermal exposure/systemic
bioavailability to TTC. Substances should be considered on a case-
by-case basis and for low level contaminants, it may be possible
to reﬁne parameters used, or apply SAR assessment rather than
requiring experimental studies. In particular, expert judgement
may be required when using the predictions for short residence
time products.
Consideration of a limited number of examples, like creams,Table 4
Predicted dermal systemic availability Qcorr expressed as mg/kg/d compared to oral TTC
Chemical Jmax (mg/cm2/h) Cosmetic use scenario Exposure time (h) Area
1,4-Dioxane 23.39 Baby shampoo 0.1 22
Hydrazine 1041.56 Face cream 24.0 56
Acrylamide 3830.21 Body lotion 24.0 1750sunscreen preparations, oil-in-water emulsions, and hair dye for-
mulations, with various degrees of saturation, a variety of vehicles
and presence of enhancers, indicates that our approach yields
predictions within an order of magnitude of experimental data for
most of the cases considered and there were few outliers. This is
despite as highlighted earlier, the Potts and Guy approach which
has some limitations for extrapolation to cosmetic formulation, as
the degree of saturation is often not known, or the vehicle can
change rapidly (e.g. volatility), that the rules do not apply and the
impact of enhancers cannot currently be modelled. For molecules
for which the experimental/predicted ratio was an outlier, it was
necessary to consider these confounding factors or ﬁrst pass
metabolism. The potential for local skin metabolism during ab-
sorption and the inﬂuence on relative oral to dermal bioavailability
may be important particularly for molecules with high dermal
absorption. In the case studies, local metabolism led to the exper-
imental availability being lower than the estimated availability, and
therefore an overly conservative prediction for butyl paraben. It is
generally believed for transdermal pharmaceuticals and cosmetics
that the low level of dermal metabolismwill increase availability of
the parent compound either in the skin or systemically compared
to oral dosing. Differences in bioavailability between dermal and
oral exposures, if signiﬁcant, could affect the application of TTC and(mg/kg/d) for three potential cosmetic impurities.
cm2 TTC class & value mg/kg/d Qcorr mg/cm2 Qcorr mg/kg/d TTC/Qcorr
5 3 or 1.5 2.34E-04 0.0081 185.25
5 geno 0.0025 1.04E-04 0.0008 2.97
0 geno 0.0025 1.80E-06 0.0004 6.25
Fig. 4. Comparison of the ratio of Q exp to Q derived from Jmax and ranked percentage absorption. The ratio Q exp (mg/cm2) to Q derived (mg/cm2) is shown. The optimum ratio
would be 1.
F.M. Williams et al. / Regulatory Toxicology and Pharmacology 76 (2016) 174e186184substance-speciﬁc toxicity data to dermal exposures. Therefore it
may be appropriate to consider the relative oral and dermal bio-
availabilities within the decision tree and deﬁne guidelines for
whether metabolism should be incorporated (IGHRC, 2006).
Currently for extrapolation of the oral TTC, an assumption is made
that oral bioavailability of chemicals in the database is high but this
is not necessarily the case for molecules which are substrates for
pre-systemically located enzymes.
There are currently limited experimental data deﬁning the rate
of absorption of cosmetics through the gut, there is information
from human tissue models such as Caco-2 cells, and from the
parallel artiﬁcial membrane permeability assay (PAMPA) (e.g.,
Th€orn et al., 2005; Cubitt et al., 2011; Rothe et al., 2014). The
evaluation becomes even more complicated when considering that
either the parent or metabolites could act with different potency on
the same or different endpoints. This aspect is seldomwell enough
characterised to be included in risk assessments based on either
speciﬁc toxicity data or on TTC. Further studies are required to
evaluate the inﬂuence of pre-systemic metabolism in skin and GI
tract on systemic availability for chemicals for which data are
available before proposing guidelines for these.
When using experimental data it is important to look critically
at the experimental data to see that the dose and time of applica-
tion are relevant to the cosmetic exposure scenario under consid-
eration. There is always uncertainty in the experimental datawhich
is reﬂected when mean and standard deviation are reported for
multiple cell experiments and for regulatory purposes, a conser-
vative value of mean plus one or two SD is often used (Navidi and
Bunge, 2002). Signiﬁcant inter-laboratory and inter-assay varia-
tion has been deﬁned for model chemicals in in vitro experiments
using human skin (van de Sandt et al., 2004). For example, in vitro
studies have shown a ten-fold range in penetration through
different samples of human skin (Lee et al., 2001) and inter-
individual and intra-individual variability in human skin barrier
function has been shown to be high (Meidan and Roper, 2008).Toxicokinetic (TK) modelling, or even physiologically-based (PB)
TK modelling, can be used to generate absorption and metabolism
parameters to ﬁll some gaps for route-to-route extrapolation. PBTK
modelling requires an extensive amount of physiological and tox-
icokinetic data on route-speciﬁc ADME processes for appropriate
calculations (Geraets et al., 2014). Furthermore, PBTK models need
to be carefully calibrated to ensure that the results are consistent
with toxicokinetic measurements, and validated against human
biomonitoring data in order to disentangle the biologically real
variability in the inter-individual toxicokinetic behaviour from the
uncertainty in the model parameters and input data. This results in
a constant process of reﬁning the PBTK model, thereby making this
a labour-intensive and time-consuming approach. However, a
number of derived models have been constructed to deﬁne the
ADME and systemic distribution kinetics of cosmetic molecules
which can be used with the decision tree to read across approaches
to apply the TTC (Gajewska et al., 2014).
The TTC is intended to be a cautious, conservative exposure level
to be used as a pragmatic tool for screening and prioritisation as a
ﬁrst step in risk assessment. It is only appropriate in cases where no
compound-speciﬁc toxicity data are available or required by regu-
lation. To be acceptable for use with TTC, predictions of systemic
availability following dermal exposure should be reliable and
similar to experimental measurements where these are available.
Recently, Partosch et al. (2015) have highlighted the usefulness of
systemic TTC values and have derived these for three datasets. A
systemic TTC value used together with the ﬂux based decision tree
to predict bioavailability may remove some of the inconsistencies
that have been seen here with example chemicals.74].
5. Conclusions
Cosmetic chemicals lend themselves to the application of oral
TTC for risk assessment where toxicity data are not available. There
is however a requirement for reliable dermal systemic availability
F.M. Williams et al. / Regulatory Toxicology and Pharmacology 76 (2016) 174e186 185data derived from an experimental absorption study or from a
prediction. We have developed a decision tree to predict ﬂux and
systemic availability based on the Potts and Guy equation with
adjustment for actual exposure. Our approach has been evaluated
for cosmetic chemicals and speciﬁc dermal exposure scenarios and
the experimental to predicted ratios were within the range of
0.1e10, which indicates ‘ﬁtness for purpose’ of the model.
For dermal exposure to low level impurities, the decision tree
can generate a prediction of bioavailability which could be used
with TTC. Our approach will need to be applied on a case by case
basis with expert judgement and in depth knowledge. Case studies
demonstrated that the model in most cases over predicts dermal
availability, but under some circumstances also under predicts. If
the TTC threshold is close to the estimated systemic bioavailability,
speciﬁc considerations and expert judgement are necessary.Conﬂict of interest disclosures
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